15 October 2020 - NDA submission is supported by positive data from two Phase 3 studies (VANISH Program) in women with vulvovaginal candidiasis.
Scynexis today announced the submission of a new drug application to the U.S. FDA for oral ibrexafungerp for the treatment of vulvovaginal candidiasis, also known as vaginal yeast infection.
As a qualified infectious disease product, ibrexafungerp is expected to receive a 6 month priority review following new drug application acceptance.